VivoSeq
Cardiovascular

Thrombocytopenic Purpura

36

Pipeline Programs↗

3

Active Trials↗

19

Companies Involved↗

Thrombocytopenic Purpura is a moderately active landscape with 36 programs across 19 companies. The most active players are Boehringer Ingelheim, Pfizer, Momenta Pharmaceuticals, Inc.. 2 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

57/100

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1M

Momenta Pharmaceuticals, Inc.

1 program

Phase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 2Roche logo

Roche

2 programs

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

33 of 40 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody38%Protein / enzyme25%Vaccine25%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.

Analysis

Trial Status

68

clinical trials

Completed51 · 75%
Unknown status8 · 12%
Terminated6 · 9%
Not yet recruiting2 · 3%
Recruiting1 · 1%

Clinical Trials

Trial Activity

68 trials

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Recruiting·SSohag University·N/A·NCT07093606·100 enrolled
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
Not yet recruiting·—·N/A·NCT06137105·100 enrolled
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
Not yet recruiting·—·N/A·NCT07059910·100 enrolled
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Completed·KKissei Pharmaceutical Co., Ltd.·Phase 3·NCT04132050·34 enrolled
Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
Completed·IInstituto Grifols, S.A.·Phase 3·NCT00699140·18 enrolled
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Completed·Novartis logoNovartis·Phase 3·NCT02201290·9 enrolled
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
Completed·HHamilton Health Sciences Corporation·Phase 2·NCT00372892·60 enrolled
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Completed·RRigel Pharmaceuticals·Phase 3·NCT02076412·74 enrolled
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
Completed·SSymphogen A/S·Phase 2·NCT00718692·61 enrolled
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00005652·20 enrolled
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Completed·GSK logoGSK·Phase 3·NCT00540423·23 enrolled
Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
Completed·CSL Behring logoCSL Behring·Phase 3·NCT00362349·19 enrolled
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Completed·Eisai logoEisai·Phase 2·NCT00441090·64 enrolled
Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)
Completed·Sanofi logoSanofi·N/A·NCT05263193·4 enrolled
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Completed·Roche logoRoche·Phase 3·NCT00770562·103 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)